Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by David E. Gerber
Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network E4512): a phase 3 trial
Get full text access Log in, subscribe or purchase for full access. References 1. Berghmans, T ∙ Paesmans, M ∙ Meert, AP ∙ et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature Lung Cancer. 2005; 49:13-23 2. Liang, W ∙ Cai, K ∙ Cao, Q ∙ et al. International expert consensus on immunotherapy for early-stage non-small cell lung cancer Transl Lung Cancer Res. 2022; 11:1742-1762 3.
Patient Perspectives on Electronic Communication of Cancer Diagnoses
Supplement 1. Supplement 2. Table 1.
Deciphering small sequence differences in T cell receptor-antigen pairing
|
Abstract T cells have important functions in development and disease processes through T cell receptor (TCR)-dependent activities. Many tools were developed to predict the binding between TCRs and antigens. However, one of the uncertainties is whether such tools can decipher how small changes in the TCRs or antigenic peptides contribute to binding. We develop a deep learning model, pMTnet-omni, which not only predicts the binding vs.
By Yi Han, Yuqiu Yang, James Z Zhu, Farjana Fattah, Mitchell von Itzstein, Minying Zhang, Casey Bermack, Peixin Jiang, Shailbala Singh, Yanhua Tian, Yifei Hu, Yafang Deng, Xiongbin Kang, Donghan M. Yang, Jialiang Liu, Chaoying Liang, Indu Raman, Chengsong Zhu, Olivia Xiao, Jonathan E. Dowell, Jade Homsi, Sawsan Rashdan, Ke Pan, Shengjie Yang, David Hsiehchen, Fangjiang Wu, John Heymach, don gibbons, Junzhou Huang, Jianjun Zhang, Cassian Yee, Alexandre Reuben, David E. Gerber, Tao Wang, Yaming Xue, Mary E. Gwin, Yvonne Gloria- McCutchen
|
Nature
Verified
Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer : A Randomized Clinical Trial
|
Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer: A Randomized Clinical Trial Supplement 1. Supplement 2. eFigure 1. Disease-free survival sensitivity analysis excluding new primary lung cancers eFigure 2. Disease-free survival in patients with negative and low tumoral PD-L1 eTable 1. Grade 3-5 Treatment-related Toxicities per CTCAE v4.0 eTable 2. Treatment-related Grade 3-5 Events Occurring in ≥ 1% of patients (n,%) Supplement 3.
By Jamie E. Chaft, Zhuoxin Sun, Charles M. Rudin, Charles Simone, Kurt R. Oettel, David Kozono, Rajitha Sunkara, Bryan Faller, James M. Isbell, Vladimir Hugec, Jeffrey M. Clarke, Ramaswamy Govindan, Jacob Sands, John Heymach, Luis E Raez, Shakun Malik, Thomas E. Stinchcombe, Sumithra J. Mandrekar, Jeffrey Bradley, David E. Gerber, Everett E Vokes, David Gandara, Charles Staley, Suresh S. Ramalingam, Onkar V. Khullar, Asheesh Shipstone, Eric C. McGary, Ashita Talsania
|
JAMA: Journal of the American Medical Association
Verified
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial
|
Abstract Over 50% of persons with unresectable stage III non-small cell lung cancer (NSCLC) treated with standard-of-care concurrent chemoradiotherapy (CCRT) and durvalumab consolidation progress or die within 18 months. Here adults with untreated, unresectable stage III NSCLC were randomized to nivolumab plus CCRT followed by consolidation with nivolumab plus ipilimumab (arm A) or nivolumab alone (arm B) or CCRT followed by consolidation with durvalumab (arm C).
By Solange Peters, Daniel Tan, David E. Gerber, James Urbanic, Suresh S. Ramalingam, Jinming Yu, Ligang Xing, Achim Rittmeyer, Tudor-Eliade Ciuleanu, Juliana Cazares de Menezes, Hye Ryun Kim, Carlos Rojas, Konstantinos Syrigos, Hidetoshi Hayashi, Diego L Cortinovis, Debora S. Bruno, Antonio Calles, Luoying Yang, Dirk De Ruysscher, Anoop Haridass, Martin Kimmich, Raheel Nathani, Geetha Pudussery
|
Nature
Verified
Profiling antigen-binding affinity of B cell repertoires in tumors by deep learning predicts immune-checkpoint inhibitor treatment outcomes - Nature Cancer
Abstract The capability to profile the landscape of antigen-binding affinities of a vast number of antibodies (B cell receptors, BCRs) will provide a powerful tool to reveal biological insights. However, experimental approaches for detecting antibody–antigen interactions are costly and time-consuming and can only achieve low-to-mid throughput.
Acknowledging and addressing real-world challenges to treating immune-related adverse events
Immune related adverse event - irAE Immune Checkpoint Inhibitor Survivorship More than a decade into the remarkable era of cancer immunotherapy, we are facing major challenges with the toxicities of the revolutionary immune checkpoint inhibitor (ICI) therapies. While ICIs have substantially improved survival rates for melanoma and lung cancer among other malignancies, we are in the nascent stage of understanding and management of their adverse events.
Trends und Herausforderungen bei der Entwicklung von Wasserstoffmotoren
1 Einleitung Individuelle Mobilität und Gütertransport stellen zwei wichtige Säulen des Wohlstandes einer Gesellschaft dar. Die Energieversorgung dieser Sektoren basiert noch zum größten Teil auf fossilen Quellen. Der damit einhergehende Ausstoß von Kohlendioxid trägt seinen Teil zum Klimawandel bei. Bereits im Jahr 2015 herrschte unter den allermeisten Nationen der Konsens, dass geeignete Gegenmaßnahmen ergriffen werden müssen, um den CO2-Ausstoß zu reduzieren 1.
Contemporary Trends in Reviewing Test Results Through the Electronic Patient Portal Among Patients With Cancer
In April 2021, the 21st Century Cures Act mandated immediate release of all medical test results to patients through electronic portals. At our cancer center, before Cures Act implementation, laboratory test results were automatically released 72 hours after posting in the electronic health record (EHR) (and could be released manually sooner), radiology results were not automatically released (after 72 hours) until 2019, and pathology results were not automatically released.
‘Tolerant fraction’ metric IDs those at risk for immunotherapy-related toxicity
You've successfully added Hematology Oncology: Gastrointestinal Cancer to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Researchers at UT Southwestern Medical Center have introduced a new metric that may be useful in predicting which patients are likely to develop immunotherapy toxicity.
Taking It to the States: Adapting Information Blocking Legislation to Oncology
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
An Updated Report on the Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer in the Surveillance, Epidemiology, and End Results Program | Oncology | JAMA Oncology | JAMA Network
An Updated Report on the Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer in the Surveillance, Epidemiology, and End Results Program The population of cancer survivors in the US continues to increase.1 Three authors of the present study reported in 2018 that 18.4% of adults newly diagnosed with cancer (2009-2013) survived a previous cancer and may therefore be excluded from cancer clinical trials.2 Many organizations3 have since recommended considering cancer survivors who...
Approaches to Continuing COVID-19-Related Clinical Research Practices After the Pandemic-Must Cinderella Leave the Ball?
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Approaches to Continuing COVID-19-Related Clinical Research Practices After the Pandemic-Must Cinderella Leave the Ball?
In January 2023, the Biden administration announced its intent to end the COVID-19 public health emergency on May 11, 2023. The sunsetting of this declaration, in place since early 2020, has numerous implications.
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study - The Lancet Oncology
Standardized eligibility criteria aim to simplify, expand access to cancer clinical trials
Source/Disclosures Disclosures: Gerber reports stock in Gilead Sciences, a consultant role with Catalyst Pharmaceuticals, advisory board roles with Daichi Sankyo, Janssen Pharmaceuticals, Mirati Therapeutics, Regeneron and Sanofi; and research funding from AstraZeneca, BerGenBio, Karyopharm Therapeutics and Sagimet Biosciences. We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Pseudoprogression in NSCLC Treated With Combo Chemotherapy
close Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel Abstract and Introduction Abstract Background: Pseudoprogression, the initial apparent worsening of cancer prior to eventual improvement, is a documented feature of immune checkpoint inhibitor administration and presents a challenge to clinicians distinguishing true progression from pseudoprogression.
Decentralized Clinical Trials in Oncology: Are We Ready for a Virtual-First Paradigm?
Introduction The COVID-19 pandemic has introduced numerous challenges to clinical practice, including potential staff and patient illness, travel restrictions, and limiting exposure for patients who may be immunocompromised.
A New Approach to Simplifying and Harmonizing Cancer Clinical Trials-Standardizing Eligibility Criteria
[Skip to Navigation] JAMA Oncol. 2022;8(9):1333-1339. doi:10.1001/jamaoncol.2022.1664 Full Text Importance Clinical trial sponsors rely on eligibility criteria to control the characteristics of patients in their studies, promote the safety of participants, and optimize the interpretation of results.
Oncologic emergencies and urgencies: A comprehensive review
Introduction There are currently 16 million Americans living with cancer who account for approximately 4 million visits to emergency departments (EDs) each year.1 Patients with advanced cancer, especially those older than 65 years, exhibit a comparatively high frailty index characterized by the prevalence of disability, multiple medical comorbidities, and ensuing polypharmacy such that the level of acuity among patients with cancer who are seeking emergency care is substantial.2 As oncology...
21st Century Cures Act: Implementation Without Understanding Implication?
I still remember the first time we lost the race. It was a few weeks after the hospital system had launched the patient portal, the secure web-based platform allowing patients to communicate directly with medical providers and view their test results. As a medical oncologist, I order many tests, including laboratory evaluations to assess treatment toxicity and radiology studies to assess treatment efficacy.
Longitudinal Experience With and Impressions of COVID-19-Related Clinical Research Changes
Abstract The COVID-19 pandemic has led to profound changes in clinical research, including remote consent, telehealth, off-site procedures, shipment of therapy, and remote study monitoring. We assessed longitudinal perceptions of these adjustments among clinical research professionals.
Application of Information Technology to Clinical Trial Evaluation and Enrollment
Abstract Importance As cancer treatment has become more individualized, oncologic clinical trials have become more complex. Increasingly numerous and stringent eligibility criteria frequently include tumor molecular or genomic characteristics that may not be readily identified in medical records, rendering it difficult to best match clinical trials with clinical sites and to identify potentially eligible patients once a clinical trial has been selected and activated.
Contemporary Lung Cancer Screening and the Promise of Blood-Based Biomarkers
Cancer Research Highlights Mitchell S. von Itzstein, David E. Gerber and John D. Minna DOI: 10.1158/0008-5472.CAN-21-0706 Published July 2021 This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below. Abstract In this issue, the study by Dagnino and colleagues represents an important addition to the maturing field of blood-based biomarkers for lung cancer screening.
Weight-based immunotherapy dosing may benefit patients with cancer and high BMI
June 22, 2021 3 min read Save Source/Disclosures Published by: Disclosures: Gerber reports no relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Taking It to the States: Adapting Information Blocking Legislation to Oncology
Dramatic pendulum swings have long characterized medical practice.
Phase 2 Study of the Focal Adhesion Kinase Inhibitor Defactinib (VS-6063) in Previously Treated Advanced KRAS Mutant Non-small Cell Lung Cancer
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 Progression-free survival. Fig. 2 Best radiographic response. Highlights •KRAS mutant non-small cell lung cancer (NSCLC) is a major unmet clinical need. •RHOA-focal adhesion kinase (FAK) pathway is a signaling axis for KRAS mutant NSCLC. •KRAS mutant NSCLC models with TP53 or CDKN2A alterations respond to FAK inhibition.
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients
Research Article David E. Gerber, Jeffrey R. Infante, Michael S. Gordon, Sarah B. Goldberg, Miguel Martín, Enriqueta Felip, Maria Martinez Garcia, Joan H. Schiller, David R. Spigel, Julie Cordova, Valerie Westcott, Yulei Wang, David S. Shames, Younjeong Choi, Robert Kahn, Randall C. Dere, Divya Samineni, Jian Xu, Kedan Lin, Katie Wood, Stephanie Royer-Joo, Vanessa Lemahieu, Eva Schuth, Anjali Vaze, Daniel Maslyar, Eric W. Humke and Howard A.
Conceptual Model for Accrual to Cancer Clinical Trials
Background The impact of clinical trials on treatment advances in cancer is diminished by suboptimal trial participation both by patients and among clinicians and their organizations.
Commentary: Clinical Trials Exclude Too Many Patients
Newswise — Not long ago, I examined an otherwise healthy and active retiree in his 50s with newly diagnosed metastatic lung cancer. He had no heart disease, no kidney disease, no liver disease. He came to my practice at UT Southwestern Medical Center specifically for clinical trial options. Disappointingly, one detail in his medical history excluded him from all of our available trials.
Too many being excluded from clinical trials for new drugs
Not long ago, I examined an otherwise healthy and active retiree in his 50s with newly diagnosed metastatic lung cancer. He had no heart disease, no kidney disease, no liver disease. He came to my practice at UT Southwestern Medical Center specifically for clinical trial options. Disappointingly, one detail in his medical history excluded him from all of our available trials.
Clinical trials exclude too many patients
The criteria that determines who can participate in clinical trials continues to grow more complex despite repeated calls to simplify them. A study conducted last year at UT Southwestern found that over the past 30 years the average number of eligibility criteria in lung cancer trials sponsored by the National Cancer Institute grew by 50 percent to an average of more than 25. Why is this occurring?
Clinical Trials Exclude Too Many Patients
Not long ago, I examined an otherwise healthy and active retiree in his 50s with newly diagnosed metastatic lung cancer. He had no heart disease, no kidney disease, no liver disease. He came to my practice at UT Southwestern Medical Center specifically for clinical trial options. Disappointingly, one detail in his medical history excluded him from all of our available trials.
Prevalence of Autoimmune Disease Among Patients With Lung Cancer
The emergence of immune checkpoint inhibitors targeting either the programmed death 1 (PD1) or cytotoxic T lymphocyte antigen 4 (CTLA4) axis represents a major therapeutic advance in treating lung cancer and other malignant diseases. These new treatments also convey risks for unpredictable, possibly severe, and potentially irreversible autoimmune toxic events that can have an effect on diverse organ systems.
Main Bronchus Location is a Predictor for Metastasis and Prognosis in Lung Adenocarcinoma: A Large Cohort Analysis
Publication HistoryPublished online: March 19, 2018Accepted: March 10, 2018; Received in revised form: February 16, 2018; Received: September 29, 2017;
Characteristics of Patients Using Patient Portals in Oncology
Research Letter March 2018 JAMA Oncol. 2018;4(3):416-418. doi:10.1001/jamaoncol.2017.5257 Nationwide, health care institutions have implemented electronic patient portals, providing patients real-time access to their health information and physicians. Portals have been studied extensively in primary care and certain specialty settings, but only recently has use in oncology been investigated.
Randomized Phase 2 Study of Tivantinib plus Erlotinib versus Single-agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-small Cell Lung Cancer - Lung Cancer
Publication HistoryPublished online: January 17, 2018Accepted: January 16, 2018; Received: December 4, 2017;
Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy
The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial
Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC
Publication HistoryPublished online: July 18, 2017Accepted: July 7, 2017; Received in revised form: July 5, 2017; Received: May 16, 2017;
TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer
EGFR inhibition leads to upregulation of TNF expression in lung cancer cell lines and xenograft tumors. Previous studies have shown that exposure of lung cancer cells to EGFR TKIs results in a rapid and biologically significant activation of NF-κB in EGFR-mutant NSCLC cells (19, 27). TNF is a key activator of NF-κB (28), and we considered the possibility that TNF may mediate the NF-κB activation triggered by EGFR inhibition.
Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Presented in part at the Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, October 30–November 1, 2014; 50th Annual Meeting of the American Society of Clinical Oncology Annual Meeting, Chicago, IL, May 30–June 3, 2014; and European Society for Medical Oncology Congress, Madrid, Spain, September 26–September 30, 2014.
Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options
Corresponding Author: David E. Gerber, MD, Division of Hematology and Oncology, Harold C. Simmons Comprehensive Cancer Center, 5323 Harry Hines Blvd, Mail Code 8852, Dallas, TX 75390-8852 (David.Gerber@UTsouthwestern.edu). Author Contributions: Dr Gerber had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Khan, Pruitt, and Gerber contributed equally to this work.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with David E.
Contact David E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack